세계의 환각제 시장 예측(-2030년) : 제품 유형별, 약물 유형별, 용도별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Psychedelic Market is accounted for $0.8 billion in 2023 and is expected to reach $2.21 billion by 2030 growing at a CAGR of 15.4% during the forecast period. Psychedelics, also known as hallucinogens, are a class of substances that alter perception, mood, and various cognitive processes. They often induce profound changes in consciousness, leading to altered thoughts, feelings, and sensory perceptions. Psychedelics have been used for centuries in various cultures for religious, spiritual, or shamanic purposes. It enhances creativity, focus, and mood.

According to the report by World Health Organization, a specialized agency of the United Nations responsible for international public health, it was estimated that, approximately 5% of Americans suffer from PTSD each year.

Market Dynamics:

Driver:

Growing acceptance of the therapeutic potential

The global increase in mental health issues and the inadequacy of existing treatments have led to a search for novel and effective therapeutic interventions. Positive outcomes and promising results from these studies have helped change the perception of psychedelics from substances of abuse to potential therapeutic agents, stimulating interest from researchers, healthcare professionals, and the pharmaceutical industry. Additionally, increased awareness and education about the potential therapeutic benefits of psychedelics have contributed to changing societal attitudes which is thereby fuelling the market growth.

Restraint:

Lack of standardization

Lack of standardized protocols for clinical trials can lead to variability in study designs, making it challenging to compare and interpret results across different trials. Determining appropriate dosages and administration methods for psychedelic substances is critical for their safe and effective use. Without standardized guidelines, there may be a lack of clarity on optimal dosages, leading to potential safety concerns or suboptimal therapeutic outcomes. This element is hindering the market from expansion.

Opportunity:

Rise in new treatment paradigms

Increased scientific interest and research in the therapeutic potential of psychedelic substances, such as psilocybin and MDMA, have led to numerous clinical trials. Positive results from these trials have garnered attention and support for psychedelic-assisted therapies. Evolving societal attitudes towards mental health and a growing acknowledgment of the limitations of traditional psychiatric treatments have shifted perceptions of psychedelics. Also, advocacy groups and patient testimonials have played a crucial role in raising awareness about the potential benefits of psychedelic-assisted therapies. The convergence of these factors has created a conducive environment for the growth of the psychedelic market

Threat:

Medical efficacy & research challenges

One of the primary research problems is to standardize dose and delivery techniques. Before psychedelic drugs are extensively utilised for therapeutic or medicinal purposes, they need to pass stringent safety and effectiveness testing in clinical studies. Public mistrust and scepticism may increase if studies on psychedelics are seen as missing scientific rigour or being inconclusive. Insurance companies could be hesitant to pay for psychedelic therapies if there isn't enough proof of their therapeutic benefits. It also reduces the variety of therapeutic alternatives that patients can choose from. The market demand is hampered by these variables.

COVID-19 Impact

The COVID-19 pandemic had negatively impacted the psychedelic market. The epidemic hampered the advancement of psychedelic research investigations and clinical trials. Lockdowns, travel restrictions, and limits on face-to-face meetings caused delays to research efforts and trials. Financial markets experienced volatility during the early phases, leading to changes in investor sentiment across various sectors, including psychedelics. In addition, a more suitable climate for the acceptance and incorporation of psychedelic treatments in the post-pandemic age was created by growing knowledge and shifting attitudes towards mental health.

The psilocybin segment is expected to be the largest during the forecast period

The psilocybin segment is estimated to have a lucrative growth. Psilocybin is primarily known for its psychedelic effects, inducing altered perceptions, sensory experiences, and changes in consciousness. It is believed to work by influencing neural pathways associated with mood regulation and emotional processing. Some studies have shown promising results, with psilocybin-assisted therapy leading to significant reductions in depressive symptoms and improved emotional well-being. Its benefits namely anxiety reduction, enhancing creativity, headache relief and heightened mindfulness fuels the segment demand.

The panic disorders segment is expected to have the highest CAGR during the forecast period

The panic disorders segment is anticipated to witness the highest CAGR growth during the forecast period, due to its integrated therapies and enhanced emotional processing. The psychedelic experience often involves a heightened sense of introspection and mindfulness. This increased awareness may help individuals confront and process their fears, fostering a greater acceptance of emotions and experiences. Many psychedelics, including psilocybin and LSD, primarily interact with serotonin receptors in the brain. This can lead to a temporary shift in the way individuals experience and process fear, potentially helping to break the cycle of panic.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. There is a growing interest in psychedelic research and development in the Asia-Pacific region, especially in the area of mental health. Additionally, there has been an increase in interest in psychedelic investments and start-ups in the area. In terms of market share and income, India leads the psychedelic drug industry. This dominance is expected to persist as the region's acceptance of these medications for the treatment of depression grows and the industry is being stimulated by rapid research development.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to expanding research trials and shifting regulatory environment. It is home for major key players such as Pfizer Inc, Celon Pharmaceuticals, Cybin Corp, Jazz Pharmaceuticals, and PharmaTher Holdings. There is a rise in the prevalence of mental illnesses like depression in North America. To further inform Canadians on the realities of mental illness, the government of Canada also runs a weekly campaign to raise awareness of the condition. North America is further anticipated to witness growth with rising mental illness and growing awareness programs.

Key players in the market:

Some of the key players profiled in the Psychedelic Market include Johnson & Johnson (J&J), Enveric Biosciences, Ceruvia Lifesciences, Apex Labs, Numinus Wellness Inc, Jazz Pharmaceuticals, Cybin Inc, Revive Therapeutics, Psychedelic Water, PharmaTher Holdings Limited, MindMed, Compass Pathways, Field Trip Health, ATAI Life Sciences, Hikma Pharmaceuticals PLC, Verrian, Celon Pharma SA, NRX Pharmaceuticals, Rose Hill Company and Psycheceutical Bioscience Inc.

Key Developments:

In November 2023, Psycheceutical Bioscience Inc announced the launch of a community crowd funding campaign on Wefunder. The campaign is currently open to all investors, and serves as the next step in Psycheceutical's mission to revolutionize mental health treatment by bringing safe, effective, and accessible psychedelic therapies to patients worldwide using precise drug delivery technologies.

In October 2023, The viral brand Psychedelic Water has launched a new product line: Psychedelic Good Mood Mix. This new product takes Psychedelic Water's award-winning kava-based alcohol alternative and brings it to a new format: a powder drink mix. Psychedelic Good Mood Mix's powder format is lightweight, making it highly portable.

In August 2023, Rose Hill Company, the leading cultivator, supplier and exporter of premium psilocybin products and biomass in Jamaica, celebrates the premier of their psychedelic wellness program, ONE Retreats, and the launch of their newest psilocybin product- the PATOO gummy. These milestones strengthen Rose Hill's total business and prime the Company for U.S. expansion.

Products Covered:

• Lysergic Acid Diethylamide (LSD)
• 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
• Phencyclidine
• Gamma Hydroxybutyric Acid (GHB)
• Etamine
• Ayahuasca
• Salvia
• Psilocybin

Drug Types Covered:

• Injectable Psychedelic Drugs
• Oral Psychedelic Drugs
• Transdermal Psychedelic Drugs
• Rectal Psychedelic Drugs
• Nasal Psychedelic Drugs

Applications Covered:

• Major Depressive Disorder
• Resistant Depression
• Panic Disorder
• Post-Traumatic Stress Disorder
• Opiate Addiction
• Narcolepsy
• Other Applications

End Users Covered:

• Specialty Clinics
• Hospitals
• Homecare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Psychedelic Market, By Product

• 5.1 Introduction
• 5.2 Lysergic Acid Diethylamide (LSD)
• 5.3 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
• 5.4 Phencyclidine
• 5.5 Gamma Hydroxybutyric Acid (GHB)
• 5.6 Etamine
• 5.7 Ayahuasca
• 5.8 Salvia
• 5.9 Psilocybin

6 Global Psychedelic Market, By Drug Type

• 6.1 Introduction
• 6.2 Injectable Psychedelic Drugs
• 6.3 Oral Psychedelic Drugs
• 6.4 Transdermal Psychedelic Drugs
• 6.5 Rectal Psychedelic Drugs
• 6.6 Nasal Psychedelic Drugs

7 Global Psychedelic Market, By Application

• 7.1 Introduction
• 7.2 Major Depressive Disorder
• 7.3 Resistant Depression
• 7.4 Panic Disorder
• 7.5 Post-Traumatic Stress Disorder
• 7.6 Opiate Addiction
• 7.7 Narcolepsy
• 7.8 Other Applications

8 Global Psychedelic Market, By End User

• 8.1 Introduction
• 8.2 Specialty Clinics
• 8.3 Hospitals
• 8.4 Homecare
• 8.5 Other End Users

9 Global Psychedelic Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Johnson & Johnson (J&J)
• 11.2 Enveric Biosciences
• 11.3 Ceruvia Lifesciences
• 11.4 Apex Labs
• 11.5 Numinus Wellness Inc
• 11.6 Jazz Pharmaceuticals
• 11.7 Cybin Inc
• 11.8 Revive Therapeutics
• 11.9 Psychedelic Water
• 11.10 PharmaTher Holdings Limited
• 11.11 MindMed
• 11.12 Compass Pathways
• 11.13 Field Trip Health
• 11.14 ATAI Life Sciences
• 11.15 Hikma Pharmaceuticals PLC
• 11.16 Verrian
• 11.17 Celon Pharma SA
• 11.18 NRX Pharmaceuticals
• 11.19 Rose Hill Company
• 11.20 Psycheceutical Bioscience Inc